Research Funding Targets Antimicrobial Resistance Crisis
A multi-year research project at MIT’s Department of Biological Engineering addresses one of the most pressing global health challenges: the growing prevalence of antibiotic-resistant superbugs.
Jameel Research, part of the Abdul Latif Jameel International network, is sponsoring the project led by Professor James J. Collins. The initiative leverages synthetic biology and artificial intelligence to create next-generation diagnostics and antibacterials to overcome antimicrobial resistance.
The US Centers for Disease Control and Prevention predicts 2 million infections and 23,000 deaths occur annually in the United States alone from antibiotic-resistant bacteria, costing $55 billion. Globally, the UK government-commissioned Review on Antimicrobial Resistance projects over 10 million deaths worldwide per year by 2050 if the crisis remains unaddressed.
The World Bank predicts up to $100 trillion of economic output may be at risk by 2050 due to antimicrobial resistance. These figures underscore the urgency of developing new antibacterials and rapid diagnostics.
Mohammed Jameel, chairman of Abdul Latif Jameel, emphasized the importance of addressing this challenge. “Antimicrobial resistance is one of the most urgent challenges we face today and addressing it will require ambitious science and sustained collaboration,” he said. “We are pleased to support this new research, building on our longstanding relationship with MIT and our commitment to advancing research across the world, to strengthen global health and contribute to a more resilient future.”
Programmable Antibacterials Through AI Design
Professor Collins serves as Termeer Professor of Medical Engineering and Science at MIT and Faculty Lead for Life Sciences at the MIT Jameel Clinic. His laboratory combines cutting-edge strengths in synthetic biology and AI to develop solutions addressing antimicrobial resistance.
The project, spanning at least three years, aims to develop and validate programmable antibacterials to overcome AMR in a range of bacterial pathogens. The approach uses AI to design minibinders that would be delivered by engineered microbes to neutralize key toxins and protein targets.
This directed design and engineering approach to antibiotic development technology advances a long-term vision to create programmable antibacterials addressing the AMR crisis. The methodology could enable more rapid development of medical countermeasures to emerging and re-emerging pathogens.
Professor Collins described the project’s significance. “This project reflects my belief that tackling AMR requires both bold scientific ideas and a pathway to real-world impact,” he said. “Jameel Research is keen to address this crisis by supporting innovative, translatable research at MIT.”
The declining antibiotic pipeline exacerbates the resistance crisis. Pharmaceutical companies have reduced investment in antibiotic development due to challenging economics: antibiotics generate lower revenues than chronic disease treatments because patients take them for short durations, while development costs remain high.
This market failure creates a role for alternative funding mechanisms. Academic research supported by philanthropic or government funding can generate early discoveries that commercial entities might subsequently develop through clinical trials and regulatory approval.
Connection to Broader Health Research Network
The antimicrobial resistance project builds on established partnership between MIT and the Jameel family. The MIT Jameel Clinic, co-founded in 2018 by MIT and Community Jameel, has become the epicenter of artificial intelligence in healthcare at the institution.
Mohammed Jameel founded Community Jameel, the international non-profit organization advancing science and learning for communities to thrive. The organization represents one of the Jameel family’s philanthropies supporting research institutions worldwide.
Previous breakthroughs at the MIT Jameel Clinic include discovery of halicin and abaucin, two new antibiotics identified through machine learning approaches. These discoveries demonstrated how AI can accelerate drug discovery by analyzing molecular structures to predict antibiotic activity.
Researchers at MIT CSAIL and the Jameel Clinic, working with techbio company Recursion, recently announced open-source release of Boltz-2. This biomolecular foundation model achieves best-in-class accuracy in predicting molecular structure and binding affinity while operating approximately 1,000 times faster than previous methods.
The speed and cost improvements give research teams more powerful tools to triage drug compounds and focus resources on the most promising candidates. Open-source release enables researchers across academia and industry to apply the technology.
The Abdul Latif Jameel Institute for Disease and Emergency Analytics at Imperial College London, co-founded with Community Jameel in 2019, complements the MIT Jameel Clinic’s work. The Jameel Institute uses data analytics to combat disease threats, having led critical modeling of COVID-19 spread during the pandemic.
The Jameel Institute launched the Jameel Institute-Kenneth C. Griffin Initiative for the Economics of Pandemic Preparedness, helping governments model economic and epidemiological impacts of public health responses to infectious disease outbreaks.
Rapid Response Capabilities for Future Outbreaks
The antimicrobial resistance research holds promise beyond addressing current resistant bacteria. The programmable antibacterial approach could enable rapid response to future outbreaks and pandemics by accelerating development of targeted countermeasures.
Emerging pathogens often require months or years to develop effective treatments using traditional drug discovery methods. AI-driven design combined with synthetic biology could compress these timelines, potentially creating new antibacterials within weeks rather than years.
This capability would prove particularly valuable during pandemics when rapid response determines how many lives can be saved. COVID-19 demonstrated that vaccines and therapeutics developed within months rather than years can dramatically reduce mortality and economic disruption.
The research project exemplifies Jameel Research’s mission: advancing work of pioneering pathfinders to create extraordinary impact on a global scale. The organization targets breakthrough thinking and emergent technologies under development at leading universities that hold significant future commercial potential.
Mohammed Jameel serves as an MIT Corporation life member, maintaining close connections to research developments at the institution. These relationships enable identification of promising research programs worthy of sustained support.
The antimicrobial resistance project addresses public health need while potentially generating intellectual property with commercial applications. Successful development of programmable antibacterials could lead to pharmaceutical partnerships, licensing agreements or spinout companies commercializing the technology.
This model of academic research generating discoveries that industry subsequently develops has proven effective across biotechnology and pharmaceutical sectors. Universities provide research capabilities and access to top scientific talent, while companies contribute development expertise, regulatory knowledge and manufacturing capacity.
Community Jameel has supported similar research-to-impact pathways across multiple domains. The Abdul Latif Jameel Water and Food Systems Lab at MIT, founded in 2014, supports and commercializes technologies addressing water and food security.
The Abdul Latif Jameel Poverty Action Lab at MIT, supported since 2005, has influenced policy affecting hundreds of millions through rigorous evaluation of poverty alleviation interventions. Co-founders Esther Duflo and Abhijit Banerjee received the 2019 Nobel Prize for Economics for their experimental approach.
Jameel Research’s focus on breakthrough technologies complements Community Jameel’s mission advancing science for community wellbeing. Both organizations pursue research with potential for real-world impact rather than purely academic inquiry.
The antimicrobial resistance crisis requires multiple approaches: developing new antibiotics, creating rapid diagnostics, implementing antimicrobial stewardship programs and improving infection prevention. No single intervention will suffice.
The MIT research project contributes one piece of this comprehensive response. Programmable antibacterials could provide new treatment options, while rapid diagnostics enable targeted antibiotic use reducing inappropriate prescriptions that drive resistance.
Professor Collins’ laboratory has established track record in synthetic biology applications addressing health challenges. The combination of synthetic biology expertise with AI capabilities positions the team to pursue ambitious approaches that might prove difficult for traditional pharmaceutical research.
The three-year initial timeline provides sustained funding enabling the team to pursue research questions requiring extended investigation. Traditional grant cycles often limit projects to shorter periods, constraining ability to undertake ambitious long-term research.
Jameel Research’s support reflects understanding that addressing antimicrobial resistance requires patient capital and willingness to fund high-risk, high-reward research. Not all approaches will succeed, but breakthrough solutions require attempting ambitious innovations.
The project’s emphasis on translation distinguishes it from purely basic research. Developing programmable antibacterials requires not only scientific innovation but also consideration of manufacturing feasibility, regulatory pathways and clinical applications.
This focus on translatable research increases likelihood that discoveries will ultimately benefit patients rather than remaining laboratory curiosities. The pathway from basic research to clinical application often proves lengthy and challenging, requiring sustained effort across multiple organizations.
Mohammed Jameel has emphasized commitment to advancing research strengthening global health. The antimicrobial resistance project exemplifies this vision, addressing urgent challenge requiring innovative solutions and sustained collaboration across disciplines and sectors.